A Phase II Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Daily Dose of Lapatinib in Advanced Breast Cancer Patients With HER-2 Non-Amplified Primary Tumours and HER-2 Positive Circulating Tumour Cells or EGFR Positive Circulating Tumor Cells.
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2012
At a glance
- Drugs Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 27 Mar 2012 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 27 Mar 2012 Actual patient number is 23 according to ClinicalTrials.gov.